Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | LY3022855 |
| Trade Name | |
| Synonyms | IMC-CS4 |
| Drug Descriptions |
LY3022855 (IMC-CS4) is a monoclonal antibody against colony stimulating factor 1 receptor (CSF1R), which potentially induces antibody-dependent cell-mediated cytotoxicity (ADCC) in tumor cells over expressing CSF1R (NCI Drug Dictionary). |
| DrugClasses | CSF1R Antibody 5 |
| CAS Registry Number | NA |
| NCIT ID | C96801 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Cobimetinib + LY3022855 + Vemurafenib | Cobimetinib LY3022855 Vemurafenib | 0 | 1 |
| Cyclophosphamide + GVAX pancreatic cancer vaccine + LY3022855 + Pembrolizumab | Cyclophosphamide GVAX pancreatic cancer vaccine LY3022855 Pembrolizumab | 0 | 1 |
| Durvalumab + LY3022855 | Durvalumab LY3022855 | 0 | 1 |
| LY3022855 | LY3022855 | 0 | 2 |
| LY3022855 + Tremelimumab | LY3022855 Tremelimumab | 0 | 1 |